Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.57 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.49 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.48 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22752027 | 0.94 | ROCK2 (0.57) | ROCK2IMPDH2CYP3A4ROCK1SIRT2 | |
| SCHEMBL20353451 | 0.86 | CYP3A4 (0.55) | IMPDH2CYP3A4RAB9ALMNAALDH1A1 | |
| SCHEMBL14124402 | 0.82 | IMPDH2 (0.64) | ROCK2IMPDH2CYP3A4ROCK1PRMT3 | |
| SCHEMBL20353520 | 0.77 | CYP3A4 (0.52) | ROCK2IMPDH2CYP3A4ROCK1RAB9A | |
| SCHEMBL20353518 | 0.77 | MEN1 (0.70) | ROCK2IMPDH2CYP3A4RAB9ALMNA | |
| SCHEMBL12058848 | 0.77 | POLB (0.65) | ROCK2IMPDH2ROCK1PRMT3LMNA | |
| SCHEMBL20525005 | 0.76 | ROCK2 (0.56) | ROCK2ROCK1 | |
| SCHEMBL22751944 | 0.76 | ROCK2 (0.56) | ROCK2ROCK1 | |
| SCHEMBL20353547 | 0.76 | BCHE (0.59) | IMPDH2CYP3A4RAB9ALMNAALDH1A1 | |
| SCHEMBL20524931 | 0.75 | CYP3A4 (0.57) | ROCK2IMPDH2CYP3A4ROCK1PRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210002253-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002253-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | ROCK2 219/4885IMPDH2 1627/4885CYP3A4 4644/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | ROCK2 219/4885IMPDH2 1627/4885CYP3A4 4644/4885 |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | ROCK2 219/4885IMPDH2 1627/4885CYP3A4 4644/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | ROCK2 219/4885IMPDH2 1627/4885CYP3A4 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.